Re: Hepalink IPO Document and what it says about RVX
posted on
Jan 28, 2020 02:49PM
It would seem that the information provided in this IPO with regards to a PH3 relating to Resverlogix is just window dressing for the IPO. I'm not sure if their license with Resverlogix allows HL to conduct a medical trial with Apabetalone on their own for any indication.
Just saying ...Koo